Shroom Boom, Tannin-Chitosan and Bucillamine; the Run on Revive Therapeutics Ltd (CNSX: RVV) (OTC: RVVTF)

Revive Therapeutics Ltd (CNSX: RVV) (OTC: RVVTF) is making a powerful move up the charts on record breaking volume after several months of choppy waters. There is currently a shroom boom happening and Revive has been making moves in the space developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity under a sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison. Revive also recently executed an exclusive research collaboration agreement with PharmaTher Inc to accelerate the development of psilocybin to treat cancer and the discovery of novel uses of undisclosed psychedelic compounds.

Revive’s wunderdrug respiratory therapeutic Bucillamine is currently a U.S. FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. Bucillamine is a respiratory therapy treatment for diseases affecting the respiratory system and the heart. Medical studies have shown Bucillamine to be 16 times more effective without lingering side effects in treating lung complications vs NAC / N-Acetyl Cysteine which is currently the go to for respiratory diseases such as Lung Cancer, Emphysema, HIV, Asthma to name just a few. There are multi-billion dollar markets waiting for Bucillamine.

Revive Therapeutics Ltd (CNSX: RVV) (OTC: RVVTF) is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis (liver disease) and the use of CBD to treat ischemia and reperfusion injury from organ transplantation. Revive newly acquired subsidiary is Psilocin Pharma Corp., the developer of production solutions for the active compound Psilocybin.  Its process encompassed with intellectual property that covers methods of production of Psilocybin based formulations.

Revive lead candidate Bucillamine is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection. Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues8 and is highly cell permeable for efficient delivery into cells.8,9 Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. Buclillamine is currently in a U.S. FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19 called “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”

Revive is making moves in the booming psychedelic space recently executing an exclusive research collaboration agreement with PharmaTher Inc to accelerate the development of psilocybin to treat cancer and the discovery of novel uses of undisclosed psychedelic compounds. The collaboration will give Revive the exclusivity to advance the research of psilocybin in the treatment of cancer and leverage PharmaTher’s panaceAI™ psychedelic discovery AI platform to screen, identify and evaluate undisclosed psychedelic compounds directed at pre-specified targets for use with Revive’s drug delivery technology. PharmaTher recently announced the filing of a U.S. provisional patent application outlining the potential novel use of psilocybin to treat cancer, which was discovered by panaceAI™.

To Find out the inside Scoop on Revive Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RVVTF

Under its sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison, Revive is developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity. The Company has finalized the prototypes and is preparing to scale for manufacturing for future clinical studies involving psilocybin and other psychedelic-derived medicines. Following several months of prototyping on a wide range of dosage forms, the Company has completed an oral thin-film strip product with psilocybin with dosage forms ranging between 1 mg and 20 mg and demonstrating its versatility through physio-chemical characterization (e.g. tensile strength of films) of bio comparable tannin-chitosan composite materials, dissolution and disintegration testing, and rate of psilocybin release from composites.   Currently technical and scientific data is being processed and finalized. Revive’s orally dissolvable thin film strip for psilocybin can be used in FDA human clinical studies and as a unique product for medical use in states where psilocybin therapy use is permitted, such as Oregon following the passage of Measure 109.

The delivery technology is a natural, non-toxic, biodegradable and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties. The delivery technology has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.

Last week Revive appointed Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”

Michael Frank, CEO of Revive stated: “We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada. Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”https://platform.twitter.com/embed/index.html?dnt=true&embedId=twitter-widget-0&frame=false&hideCard=false&hideThread=false&id=1336136033172275202&lang=en&origin=https%3A%2F%2Fmicrocapdaily.com%2Fshroom-boom-tannin-chitosan-and-bucillamine-the-run-on-revive-therapeutics-ltd-cnsx-rvv-otc-rvvtf%2F129224%2F&theme=light&widgetsVersion=ed20a2b%3A1601588405575&width=550px

For More on Revive Subscribe Right Now!

Revive is making a powerful move up the charts on record breaking volume after several months of choppy waters. There is currently a shroom boom happening and Revive has been making moves in the space developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity under a sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison. Revive also recently executed an exclusive research collaboration agreement with PharmaTher Inc to accelerate the development of psilocybin to treat cancer and the discovery of novel uses of undisclosed psychedelic compounds. Revive’s wunderdrug respiratory therapeutic Bucillamine is currently a U.S. FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. Bucillamine is a respiratory therapy treatment for diseases affecting the respiratory system and the heart. Medical studies have shown Bucillamine to be 16 times more effective without lingering side effects in treating lung complications vs NAC / N-Acetyl Cysteine which is currently the go to for respiratory diseases such as Lung Cancer, Emphysema, HIV, Asthma to name just a few. There are multi-billion dollar markets waiting for Bucillamine. We will be updating on Revive on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with Revive.

SOURCE MICROCAP DAILY

CANDLR REVIVE THERAPEUTICS COMPANY PROFILE+